Lilly Collaborates with Verge Genomics to Develop ALS Therapies
By Ashish Tripathi
Pharma Deals Review: Vol 2021 Issue 9 (Table of Contents)
Published: 14 Sep-2021
DOI: 10.3833/pdr.v2021.i9.2635 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its neuroscience pipeline, Eli Lilly has entered in a research collaboration agreement to discover, develop and commercialise new therapies for the treatment of amyotrophic lateral sclerosis (ALS)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018